Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With<i>NPM1</i>Mutation: A Study by the Acute Leukemia French Association GroupMarie Balsat, Nicolas Boissel, Emmanuel Raffoux et al.|Journal of Clinical Oncology|2017Cited by 292
Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO StudyPatrice Chevallier, Philippe Rousselot, Thibault Leguay et al.|Blood|2022Cited by 32
Genetic alterations and MRD refine risk assessment for <i>KMT2A</i>-rearranged B-cell precursor ALL in adults: a GRAALL studyRathana Kim, Emmanuelle Clappier, Hugo Bergugnat et al.|Blood|2023Cited by 29
Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2Nicolas Boissel, Hervé Dombret, Françoise Huguet et al.|Blood|2021Cited by 23
Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B StudyNicolas Boissel, Hervé Dombret, Françoise Huguet et al.|Blood|2022Cited by 23